Quinn Opportunity Partners LLC Acquires New Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Quinn Opportunity Partners LLC purchased a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 380,000 shares of the biotechnology company's stock, valued at approximately $581,000. Quinn Opportunity Partners LLC owned about 0.25% of Heron Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of HRTX. JPMorgan Chase & Co. lifted its stake in shares of Heron Therapeutics by 295.8% during the third quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company's stock valued at $411,000 after buying an additional 154,487 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of Heron Therapeutics by 456.5% during the 3rd quarter. Principal Financial Group Inc. now owns 102,651 shares of the biotechnology company's stock worth $204,000 after acquiring an additional 84,205 shares during the period. Verition Fund Management LLC grew its holdings in Heron Therapeutics by 340.0% in the third quarter. Verition Fund Management LLC now owns 108,115 shares of the biotechnology company's stock valued at $215,000 after purchasing an additional 83,542 shares during the period. Congress Park Capital LLC grew its holdings in Heron Therapeutics by 24.1% in the fourth quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company's stock valued at $3,757,000 after purchasing an additional 477,417 shares during the period. Finally, Barclays PLC increased its position in Heron Therapeutics by 29.8% during the third quarter. Barclays PLC now owns 218,455 shares of the biotechnology company's stock worth $434,000 after purchasing an additional 50,109 shares during the last quarter. 80.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently issued reports on HRTX shares. StockNews.com cut shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th. Needham & Company LLC restated a "buy" rating and set a $4.00 price target on shares of Heron Therapeutics in a research note on Friday, April 11th.

Heron Therapeutics Stock Performance

Shares of NASDAQ:HRTX traded down $0.03 during mid-day trading on Thursday, hitting $1.82. 431,646 shares of the company traded hands, compared to its average volume of 1,658,345. The firm's 50 day simple moving average is $2.07 and its 200 day simple moving average is $1.78. The firm has a market cap of $276.48 million, a P/E ratio of -10.08 and a beta of 1.39. Heron Therapeutics, Inc. has a 52-week low of $1.04 and a 52-week high of $3.93.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.05. The firm had revenue of $40.78 million during the quarter, compared to analysts' expectations of $37.37 million. Equities research analysts expect that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.